BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2022 8:29:04 AM | Browse: 429 | Download: 826
Publication Name World Journal of Gastroenterology
Manuscript ID 77938
Country Japan
Received
2022-05-30 13:03
Peer-Review Started
2022-05-30 13:05
To Make the First Decision
Return for Revision
2022-06-18 18:54
Revised
2022-07-16 05:56
Second Decision
2022-08-08 03:09
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-08-17 21:37
Articles in Press
2022-08-17 21:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2022-08-28 23:47
Publish the Manuscript Online
2022-09-07 08:29
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy
Manuscript Source Invited Manuscript
All Author List Masahiro Iizuka, Takeshi Etou and Shiho Sagara
ORCID
Author(s) ORCID Number
Masahiro Iizuka http://orcid.org/0000-0002-4920-2805
Takeshi Etou http://orcid.org/0000-0001-8402-7689
Shiho Sagara http://orcid.org/0000-0002-1900-7937
Funding Agency and Grant Number
Corresponding Author Masahiro Iizuka, MD, PhD, Director, Doctor, Akita Health Care Center, Akita Red Cross Hospital, 3-4-23 Nakadori, Akita 010-0001, Japan. maiizuka@woody.ocn.ne.jp
Key Words Ulcerative colitis; Inflammatory bowel disease; Cytapheresis; Granulocyte and monocyte adsorptive apheresis; Anti-tumor necrosis factor-α antibody; Combination therapy
Core Tip Management of refractory ulcerative colitis (UC) experiencing primary non-response or loss of response to biologics is a critical issue. We first summarized the efficacy of cytapheresis (CAP) for such patients. Although CAP tended to have lower effects for induction of remission in patients with UC who were refractory to biologics, combination therapies with CAP and biologics induced clinical remission or response in more than 40% of such patients with UC on average. Given the excellent safety profile of CAP, we believe that this combination therapy can be an alternative therapeutic strategy for such refractory UC patients.
Publish Date 2022-09-07 08:29
Citation Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972
URL https://www.wjgnet.com/1007-9327/full/v28/i34/4959.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i34.4959
Full Article (PDF) WJG-28-4959.pdf
Full Article (Word) WJG-28-4959.docx
Manuscript File 77938_Auto_Edited-LS.docx
Answering Reviewers 77938-Answering reviewers.pdf
Audio Core Tip 77938-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 77938-Conflict-of-interest statement.pdf
Copyright License Agreement 77938-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 77938-Language certificate.pdf
Peer-review Report 77938-Peer-review(s).pdf
Scientific Editor Work List 77938-Scientific editor work list.pdf